Healthcare & Life Sciences

USPTO Trademark Publication: BORN IN MAYFAIR

The USPTO has published the trademark application for "BORN IN MAYFAIR" for opposition. The application covers a wide range of services including business management of hotels, resorts, and restaurants, as well as financial services, real estate, and hospitality operations. The publication date is March 20, 2026.

USPTO Trademark Application Published for Opposition

The USPTO has published a trademark application for lighting apparatus and related goods for opposition. The application, identified by TM79429596, was published on March 20, 2026, and is now open for potential objections from third parties.

EXOLASE Trademark Published for Opposition - Medical Services

The United States Patent and Trademark Office (USPTO) has published the trademark application for 'EXOLASE' for opposition. The application covers a wide range of medical, health, and beauty services, as well as various medical apparatus and devices.

USPTO Trademark Publication: Hanen Launchpad to Literacy

The United States Patent and Trademark Office (USPTO) has published the trademark application for 'Hanen Launchpad to Literacy' for opposition. This trademark covers a wide range of educational materials and services related to language and literacy development in children.

USPTO Trademark Publication for Opposition - Medical Services

The USPTO has published trademark application 79436936 for opposition, covering a broad range of medical services and equipment. The application was published on March 20, 2026, with a filing date of August 21, 2025.

USPTO Trademark Publication for Opposition: TM79436743

The USPTO has published trademark application TM79436743 for opposition, with a publication date of March 20, 2026. The application covers a range of medical and pharmaceutical services, as well as scientific research and development information.

USPTO Trademark Publication: INUVETA

The USPTO has published the trademark application for 'INUVETA' for opposition. The application covers a wide range of services including online marketplaces, digital fitness studios, AI-powered virtual assistants, and telecommunication services.

CELLCOLABS Trademark Published for Opposition

The USPTO has published the trademark application for CELLCOLABS for opposition. The application covers human healthcare services, medical services related to cell removal, treatment, and processing, and cultured cell bank services for medical transplantation. The filing date was August 21, 2025.

USPTO Trademark Application Published for Opposition: TERRE EN UE

The United States Patent and Trademark Office (USPTO) has published the trademark application "TERRE EN UE" for opposition. The application covers a broad range of services including entertainment, sporting, cultural activities, health club services, restaurant services, and transportation.

USPTO Trademark Application Published for Opposition: Solana

The USPTO has published a trademark application for 'Solana' for opposition. The application covers agricultural products, renewable energy technology services, and energy generation. The publication initiates a period during which third parties can oppose the trademark registration.

Fresh Health Trademark Application Published for Opposition

The United States Patent and Trademark Office (USPTO) has published the trademark application for "Fresh Health" for opposition. The application covers a wide range of goods and services, including fitness classes, health club services, cosmetic and personal care products, medical research, software, and printed matter.

Xenia Trademark Application Published for Opposition

The USPTO has published the Xenia trademark application (TM79424441) for opposition. The application, filed on April 23, 2025, covers tree-nursery services including propagation and cultivation of fruit trees and related products. The publication date is March 20, 2026.

USPTO Trademark Publication: GG NYX EOS for Medical Services

The USPTO has published the trademark application "GG NYX EOS" for medical assistance and related technology services. The application was published for opposition on March 20, 2026, following a filing date of September 15, 2025.

HERDNET Trademark Application Published for Opposition

The USPTO has published the trademark application for HERDNET, which covers software and hardware for livestock monitoring and management, for opposition. The application was filed on October 3, 2025, and the publication date is March 20, 2026.

QUIN Trademark Application Published for Opposition

The USPTO has published the QUIN trademark application for opposition. The application covers a broad range of IT services, software development, and medical services, including AI-driven diagnostic and treatment tools. The publication marks a step in the trademark registration process, allowing third parties to oppose the mark.

USPTO Trademark Publication: MUCOTEST

The USPTO has published the trademark application for MUCOTEST for opposition. The application covers a wide range of pharmaceutical, medical, and veterinary preparations, as well as medical and veterinary services. The publication marks a step in the trademark registration process.

Mimetrik Trademark Application Published for Opposition

The United States Patent and Trademark Office (USPTO) has published the trademark application for "Mimetrik" for opposition. The application covers dental prostheses, instruments, software for dental imaging and manufacturing, and related services.

USPTO Trademark Application for 54 Reasons Medical Services

The USPTO has published a trademark application for '54 Reasons' covering a broad range of medical, health, transportation, educational, and entertainment services. The application is now open for opposition, with a publication date of March 20, 2026.

NEUROKIT POWERED BY CHDR Trademark Published for Opposition

The United States Patent and Trademark Office (USPTO) has published the trademark application for NEUROKIT POWERED BY CHDR for opposition. The application covers various medical instruments and software related to monitoring central nervous system functions.

PREVIDI AI Trademark Application for Intent to Use

The USPTO has received an intent-to-use trademark application for "PREVIDI AI" filed by an unspecified applicant. The application covers health care consulting services, specifically life care planning for individuals with catastrophic and long-term medical needs.

QBMOBILE Trademark Application for Medical Services

The USPTO has published a trademark application for QBMOBILE, filed on October 16, 2024, for medical consultancy services related to behavioral and neurodevelopmental disorders. The application was published for opposition on March 20, 2026.

JAPA VALLEY Trademark Published for Opposition

The United States Patent and Trademark Office (USPTO) has published the JAPA VALLEY trademark application for opposition. This publication marks a procedural step in the trademark registration process, allowing third parties to file objections if they believe the mark would cause confusion or harm.

David Lloyd Trademark Application Published for Opposition

The United States Patent and Trademark Office (USPTO) has published the trademark application TM79438921 for David Lloyd, covering a wide range of goods and services including clothing, health and beauty care, digital publications, restaurant services, fitness, and sporting goods. The publication opens a period for opposition before the trademark can be officially registered.

USPTO Trademark Publication: ONESELF - Medical Services

The USPTO has published the trademark application for "ONESELF" for opposition, covering medical services including pathology, health assessment, and nutritional advice. The application was filed on July 18, 2025, and published on March 20, 2026.

USPTO Trademark Application 79435612 Published for Opposition

The United States Patent and Trademark Office (USPTO) has published trademark application 79435612 for opposition. This application covers a broad range of goods and services, including clothing, agricultural implements, veterinary services, metal building materials, construction services, and digital media. The publication date is March 20, 2026.

Minnesota Updates Fish Consumption Guidelines for Mercury and PFAS

The Minnesota Department of Health (MDH) has updated its fish consumption guidelines due to new analyses of mercury and PFAS in fish tissue. The updated guidelines include new length-based recommendations for walleye and northern pike, more protective guidelines for Northeast Minnesota, and specific guidance for the Vermillion River.

NY DOH Announces New Mental Health Training for First Responders

The New York State Department of Health has released a new online training program for mental health professionals aimed at improving support for first responders. The training focuses on first responder culture, mental health challenges, and barriers to seeking treatment, and is available statewide.

NY DOH Update on Federal Approval to Preserve Health Coverage

The New York State Department of Health announced federal approval from CMS to transition back to Basic Health Program authority, preserving coverage for 1.3 million New Yorkers. Approximately 450,000 individuals will lose eligibility for the Essential Plan and transition to Qualified Health Plans starting July 1, 2026, due to federal funding changes.

USPTO Patent Grant: Immunopotentiating Amino Acid Mineral Complex

The USPTO has granted a patent (US12583873B2) to BTN CO., LTD. for an amino acid mineral complex with immunopotentiating activity. This complex can be used in compositions for foods, pharmaceuticals, or feeds to enhance immunity or antibody production in humans and animals.

USPTO Grants Patent for Sodium Oxybate to Treat Idiopathic Hypersomnia

The United States Patent and Trademark Office (USPTO) has granted patent US12582622B2 to Jazz Pharmaceuticals Ireland Limited for methods of treating idiopathic hypersomnia with sodium oxybate. The patent is effective March 24, 2026.

USPTO Patent Grant for Viral Infection Compounds Targeting Sigma Receptors

The USPTO has granted a patent (US12582619B2) to Thomas Jefferson University for compounds that modulate Sigma receptors to treat viral infections. The patent covers methods for preventing, treating, or ameliorating viral infections using these compounds, potentially in combination with other therapeutic agents.

USPTO Grants Patent for Benzothiazole Compound for Parkinson's and Restless Leg Syndrome

The USPTO has granted a patent (US12583829B2) to Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. for a salt of a benzothiazole compound and its crystal form. The patent covers the use of this compound in the preparation of drugs for treating Parkinson's disease and restless leg syndrome.

USPTO Patent Grant for GIP Receptor Antibodies

The USPTO has granted patent US12583930B2 to Crystal Bioscience Inc. for GIP receptor antibodies designed to treat metabolic disorders, specifically those related to glucose metabolism. The patent covers antibodies that bind to and inhibit the human glucose-dependent insulinotropic polypeptide (GIP) receptor.

USPTO Patent Grant: ARDS Treatment with G-CSF Inhibitors

The USPTO has granted patent US12583929B2 to CSL Innovation Pty Ltd for methods of treating acute respiratory distress syndrome (ARDS) using compounds that inhibit G-CSF signaling. The patent covers compounds and their use in manufacturing medicaments for ARDS prevention and treatment.

USPTO Patent for Alzheimer's Treatment Using LRP1/SorLA Antagonist

The USPTO has granted a patent (US12583920B2) to the University of Maryland, Baltimore, for methods and compositions to treat or prevent Alzheimer's disease using LRP1 and/or SorLA antagonists. The patent covers specific therapeutic approaches targeting tau internalization and trafficking in neuronal cells.

USPTO Grants Patent for Flavivirus Cross Neutralizing Antibody

The USPTO has granted patent US12583912B2 for a flavivirus cross-neutralizing antibody developed by the Japan Institute for Health Security. This antibody specifically targets the E protein of flaviviruses, including Zika, dengue, and Japanese encephalitis viruses, and aims to control infection with suppressed Antibody-Dependent Enhancement (ADE).

USPTO Patent Granted for Cognitive Disorder Treatment Compound

The USPTO has granted patent US12583884B2 to AELIS FARMA for a compound, 3beta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-one, for use in treating cognitive disorders. The patent filing date was December 18, 2019.

USPTO Patent Grant: Tumor Treatment with Antibodies

The USPTO has granted patent US12582713B2 to Bristol-Myers Squibb Company for methods of treating tumors using pharmaceutical compositions containing anti-PD-1 or anti-PD-L1 antibodies, particularly for subcutaneous delivery. The patent also covers compositions that include an endoglycosidase hydrolase enzyme.

USPTO Grants Patent for Glutathione Trisulfide in Neuroprotection

The USPTO has granted a patent (US12582693B2) to The General Hospital Corporation for methods using glutathione trisulfide (GSSSG) in neuroprotection. The patent covers uses in treating neurodegenerative diseases and reducing ischemic injury risk.

USPTO Patent Grant: Botulinum Toxin for Infertility Treatment

The USPTO has granted a patent (US12582705B2) to CHA UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION for a composition comprising botulinum toxin or a salt thereof. This composition is intended to increase endometrial blood flow and improve implantation potential, potentially treating subfertility or infertility.

Patent for Crohn's Disease Indicator and Treatment

The USPTO has granted Washington University a patent (US12582696B2) for methods to treat, select, and monitor inflammatory bowel disease using Debaryomyces species as a biomarker. The treatment involves administering an antifungal compound and detecting fungal DNA or antibodies.

USPTO Patent Grant: Peptides for Treating Glioma Tumors

The USPTO has granted patent US12582695B2 for peptides, compositions, and methods to treat glioma tumors infiltrated with macrophages. The patent was filed on November 27, 2019, and is assigned to Instytut Biologii Doświadczalnej im. Marcelego Nenckiego Polska Akademia Nauk.

USPTO Grants Patent for Compounds Inhibiting Protozoan Parasites

The USPTO has granted a patent (US12582694B2) to the University of South Florida for compounds and methods designed to block protozoan parasite invasion and liver-stage development, specifically mentioning Plasmodium falciparum. This patent covers novel therapeutic approaches for treating parasitic infections.

USPTO Patent Grant US12582691B2: Yunnan Baiyao/Xingnaojing for TBI

The USPTO has granted patent US12582691B2 to Lotus Biotech.com LLC for methods of administering Yunnan Baiyao or Xingnaojing to patients with moderate-to-severe traumatic brain injury (TBI) and craniotomy. The patent covers methods for improving postoperative recovery and inhibiting adverse impacts associated with TBI and related neurological conditions.

USPTO Patent Grant: Cancer Treatment Compositions

The USPTO has granted a patent (US12582690B2) to the Korea Institute of Science and Technology for compositions containing Rubus longisepalus var. tozawai extracts for preventing or treating cancer. The patent details specific anticancer efficacy against various cancers, including diffuse-type gastric cancer.

USPTO Grants Patent for Terpenoids in Fibrotic Disease Treatment

The USPTO has granted patent US12582689B2 to ARJIL BIOTECH HOLDING COMPANY LIMITED for a method of treating or preventing fibrotic diseases using terpenoids extracted from Antrodia-camphorate or Anisomeles indica. The patent was granted on March 24, 2026.

USPTO Patent Grant: Bone Fracture Recovery Composition Manufacturing Method

The USPTO has granted a patent (US12582686B2) for a manufacturing method of a composition designed to promote bone fracture recovery. The method involves preparing and processing a specific mixture of herbal and natural ingredients into a liquid extract.

USPTO Patent Grant: Allergy Treatment Compositions

The USPTO has granted patent US12582679B2 to Vedanta Biosciences, Inc. for compositions and methods for treating allergy, including food allergy. The patent covers novel approaches to modulating immune responses and inducing immune tolerance or desensitization.

Immunotherapy Patent for H3K27M Mutation Cancers Issued

The USPTO has issued a new patent (US12582675B2) to The Board of Trustees of the Leland Stanford Junior University for methods of treating cancers harboring an H3K27M mutation using immunotherapy. The patent details the use of immune cells engineered to express GD2-specific chimeric antigen receptors.

Vanadium Compounds Patented for Cancer Treatment

The USPTO has granted a patent (US12582672B2) to The Broad Institute, Inc. for vanadium compositions and methods for treating cancers, particularly those expressing elevated levels of SLC26A2. The patent covers the use of bis(maltolato)oxovanadium(IV) (BMOV) and related compounds.